PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634493
PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634493
Gastroenteropancreatic Neuroendocrine Tumors | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs), also known as carcinoids and islet cell tumours, are tumors derived from neuroendocrine cells that can appear anywhere along the gastrointestinal tract. They are a family of heterogeneous neoplasms with a wide range of clinical behaviour. Globally, NET incidence and incidence are rising, with the USA, Canada, and Norway seeing the fastest rates of growth. The term gastroenteropancreatic neuroendocrine tumors (GEP-NETs) refers to a variety of tumor types, including those that are either aggressive and poorly differentiated or indolent and well differentiated.
Description
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs), also known as carcinoids and islet cell tumours, are tumors derived from neuroendocrine cells that can appear anywhere along the gastrointestinal tract. They are a family of heterogeneous neoplasms with a wide range of clinical behaviour. Less frequently occurring than GEP-NETs are a number of other gastrointestinal tract tumors, including combined stomach and pancreatic carcinomas. Their age at diagnosis is frequently younger than for carcinomas (5th decade), and they can arise spontaneously or as a result of inherited predisposition disorders like multiple endocrine neoplasia type 1, von Hippel-disease, Lindau's, or neurofibromatosis type 1.
Gastroenteropancreatic Neuroendocrine Tumors (Epidemiology)
The incidence and incidence of NETs are increasing worldwide, with the United States, Canada, and Norway experiencing the fastest rates of increase. In the United States alone, the incidence of NETs has more than doubled in the past 40 years, and local rather than metastatic tumors are occurring more frequently. Currently, there are approximately 170,000 cases in Korea. GEP NETs are the most common NET subtype, accounting for 55% to 70% of all NETs.
Gastroenteropancreatic Neuroendocrine Tumors -Current Market Size & Forecast Trends
The market for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is projected to grow significantly, with the market size estimated at approximately USD 2.8 billion in 2020 and expected to reach around USD 5.6 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 7.5%. This growth is driven by increasing awareness of GEP-NETs, advancements in diagnostic techniques, and the development of novel therapies targeting these tumors. The U.S. accounts for a substantial portion of the market, representing about 64% of the overall GEP-NETs market in 2020. Key players in the market include companies like Novartis, Bristol-Myers Squibb, and Merck, which are actively developing new treatments to address unmet needs in this area. As research continues and more therapies are introduced, the GEP-NETs market is well-positioned for robust expansion through 2035.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a diverse group of tumors that can be aggressive and poorly differentiated or slow-growing and well-differentiated. Somatostatin analogues are typically used as the first-line treatment for GEP-NETs if the tumor expresses somatostatin receptors and is well differentiated. Lutetium dotatate is approved for second-line therapy as supported by the NETTER-1 study. If the liver is the area of the body where the disease is most prevalent, liver embolization may be an effective second-line therapy. There are many systemic treatment options for pancreatic NETs. Due to the RADIANT-3 study, both somatostatin analogues and everolimus have been approved. Sunitinib has also been authorized as a therapy for pancreatic NETs. Capecitabine and temozolomide make up a very powerful chemotherapy cocktail. Peptide receptor radionuclide therapy offers significantly higher response rates and longer progression-free survival than some systemic therapies, according to more recent technology. In the NET01 study, the response rate was 18% higher than with everolimus or chemotherapy.
Report Highlights
Gastroenteropancreatic Neuroendocrine Tumors - Current Market Trends
Gastroenteropancreatic Neuroendocrine Tumors - Current & Forecasted Cases across the G8 Countries
Gastroenteropancreatic Neuroendocrine Tumors - Market Opportunities and Sales Potential for Agents
Gastroenteropancreatic Neuroendocrine Tumors - Patient-based Market Forecast to 2035
Gastroenteropancreatic Neuroendocrine Tumors - Untapped Business Opportunities
Gastroenteropancreatic Neuroendocrine Tumors - Product Positioning Vis-a-vis Competitors' Products
Gastroenteropancreatic Neuroendocrine Tumors - KOLs Insight
Table of Content
1. Gastroenteropancreatic Neuroendocrine Tumors Background
- 1.1. Gastroenteropancreatic Neuroendocrine Tumors Definition
- 1.2. Signs and Symptoms
- 1.3. Pathogenesis
- 1.4. Clinical Manifestation
- 1.5. Gastroenteropancreatic Neuroendocrine Tumors biomarkers
- 1.6. Diagnosis
2. Epidemiology Estimated and Forecast to 2035
- 2.1. Epidemiology Research Method & Data Sources Used
- 2.2. United States
- 2.2.1. Incident Cases of Gastroenteropancreatic Neuroendocrine Tumors
- 2.2.2. Diagnosed and treatable cases of Gastroenteropancreatic Neuroendocrine Tumors by line of therapies (LOT)
- 2.3. United Kingdom
- 2.3.1. Incident Cases of Gastroenteropancreatic Neuroendocrine Tumors
- 2.3.2. Diagnosed and treatable cases of Gastroenteropancreatic Neuroendocrine Tumors by line of therapies (LOT)
- 2.4. Spain
- 2.4.1. Incident Cases of Gastroenteropancreatic Neuroendocrine Tumors
- 2.4.2. Diagnosed and treatable cases of Gastroenteropancreatic Neuroendocrine Tumors by line of therapies (LOT)
- 2.5. Germany
- 2.5.1. Incident Cases of Gastroenteropancreatic Neuroendocrine Tumors
- 2.5.2. Diagnosed and treatable cases of Gastroenteropancreatic Neuroendocrine Tumors by line of therapies (LOT)
- 2.6. France
- 2.6.1. Incident Cases of Gastroenteropancreatic Neuroendocrine Tumors
- 2.6.2. Diagnosed and treatable cases of Gastroenteropancreatic Neuroendocrine Tumors by line of therapies (LOT)
- 2.7. Italy
- 2.7.1. Incident Cases of Gastroenteropancreatic Neuroendocrine Tumors
- 2.7.2. Diagnosed and treatable cases of Gastroenteropancreatic Neuroendocrine Tumors by line of therapies (LOT)
- 2.8. Japan
- 2.8.1. Incident Cases of Gastroenteropancreatic Neuroendocrine Tumors
- 2.8.2. Diagnosed and treatable cases of Gastroenteropancreatic Neuroendocrine Tumors by line of therapies (LOT)
- 2.9. China
- 2.9.1. Incident Cases of Gastroenteropancreatic Neuroendocrine Tumors
- 2.9.2. Diagnosed and treatable cases of Gastroenteropancreatic Neuroendocrine Tumors by line of therapies (LOT)
- 2.10. Current Unmet Needs in Gastroenteropancreatic Neuroendocrine Tumors
3. Current Treatment Paradigm
- 3.1. Treatment/Prevention guidelines
- 3.2. Regulatory Approvals/Indication and Current Benchmarks
4. KOLs Insight (US, EU, JP, CH)
- 4.1. Unmet Needs
- 4.2. Analysis of the progress in terms of approvals & current pipeline
- 4.3. Impact on the treatment algorithm and product positioning
- 4.4. Relevance of new targets/platforms/ Therapy Uptake Share %
- 4.5. Physicians Preferences for the new pharmacological agents
5. What's New in 2024/2025
6. Future Treatment Paradigm
- 6.1. Gastroenteropancreatic Neuroendocrine Tumors Competitor Landscape and Approvals Anticipated
- 6.2. Future Treatment Algorithms and Competitor Positioning
- 6.3. Key Data Summary for Emerging Treatment
7. Late Phase Therapies Strategic Considerations in Gastroenteropancreatic Neuroendocrine Tumors
8. Total Market Forecast
- 8.1. Key Summary Findings
- 8.1.1. G8 total Market for Gastroenteropancreatic Neuroendocrine Tumors 2022-2035 (USD Million)
- 8.1.2. G8 total Market for Gastroenteropancreatic Neuroendocrine Tumors by Therapies 2022-2035 (USD Million)
9. Market Forecast by Country
- 9.1. United States
- 9.1.1. United States Market for Gastroenteropancreatic Neuroendocrine Tumors 2022-2035 (USD Million)
- 9.1.2. United States Market for Gastroenteropancreatic Neuroendocrine Tumors by Therapies 2022-2035 (USD Million)
- 9.2. Germany
- 9.2.1. Germany Market for Gastroenteropancreatic Neuroendocrine Tumors 2022-2035 (USD Million)
- 9.2.2. Germany Market for Gastroenteropancreatic Neuroendocrine Tumors by Therapies 2022-2035 (USD Million)
- 9.3. France
- 9.3.1. France Market for Gastroenteropancreatic Neuroendocrine Tumors 2022-2035 (USD Million)
- 9.3.2. France Market for Gastroenteropancreatic Neuroendocrine Tumors by Therapies 2022-2035 (USD Million)
- 9.4. Italy
- 9.4.1. Italy Market for Gastroenteropancreatic Neuroendocrine Tumors 2022-2035 (USD Million)
- 9.4.2. Italy Market for Gastroenteropancreatic Neuroendocrine Tumors by Therapies 2022-2035 (USD Million)
- 9.5. Spain
- 9.5.1. Spain Market for Gastroenteropancreatic Neuroendocrine Tumors 2022-2035 (USD Million)
- 9.5.2. Spain Market for Gastroenteropancreatic Neuroendocrine Tumors by Therapies 2022-2035 (USD Million)
- 9.6. United Kingdom
- 9.6.1. United Kingdom Market for Gastroenteropancreatic Neuroendocrine Tumors 2022-2035 (USD Million)
- 9.6.2. United Kingdom Market for Gastroenteropancreatic Neuroendocrine Tumors by Therapies 2022-2035 (USD Million)
- 9.7. Japan
- 9.7.1. Japan Market for Gastroenteropancreatic Neuroendocrine Tumors 2022-2035 (USD Million)
- 9.7.2. Japan Market for Gastroenteropancreatic Neuroendocrine Tumors by Therapies 2022-2035 (USD Million)
- 9.8. China
- 9.8.1. China Market for Gastroenteropancreatic Neuroendocrine Tumors 2022-2035 (USD Million)
- 9.8.2. China Market for Gastroenteropancreatic Neuroendocrine Tumors by Therapies 2022-2035 (USD Million)
10. Market Drivers and Barriers
